ProstaScint scan for staging prostate cancer

Urology

Volumn 57, Issue 3, 2001, Pages 402-406

  Lange, Paul H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

CANCER RADIOTHERAPY; CANCER STAGING; EDITORIAL; HUMAN; LYMPH NODE METASTASIS; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY;

EID: 0035123206     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)01109-2     Document Type: Editorial

References (46)

1. Localization of human renal cell carcinoma xenografts with a tumor preferential monoclonal antibody
2. Dosimetry and pharmacokinetics of monoclonal antibody A6H with human renal cell carcinoma xenografts; single dose study
3. Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts
4. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination and evaluation of biotinylated starburst dendrimers
5. Immunoscintigraphy with indium-111-capromab pendetide; evaluation before definitive therapy in patients with prostate cancer
6. Experimental studies of radioimmunodetection of cancer; an overview
7. Trials and tribulations; oncological antibody imaging comes to the fore
8. A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging
9. Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice
10. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts
11. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in renal-cell carcinoma xenografts; relative effects of size and affinity
12. Preclinical evaluation of immunoconjugates
13. Lymphoma, melanoma, colon cancer; diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P Pendergrass New Horizons Lecture
14. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors
15. Antibody localization in human renal cell carcinoma; a phase I study of monoclonal antibody G250
16. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy
17. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
18. Comparison of prostate specific membrane antigen and prostate specific antigen levels in prostate cancer patients
19. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer
20. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts
21. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumor; significance of elevated interstitial pressure
22. 2 fragments
23. Quantitative analysis of antibody localization in human metastatic colon cancer; a phase I study of monoclonal antibody A33
24. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen; positron emission tomography and biopsy correlation
25. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen
26. The role of monoclonal antibody in the management of prostate adenocarcinoma
27. Multicenter radioimmunoscintigraphic evaluation of patients with primary prostate cancer using indium In-111-capromab pendetide
28. 111indium-labeled monoclonal antibody CYT-356
29. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
30. Prostate specific antigen and local recurrence after radical prostatectomy
31. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy
32. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy
33. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy
34. Radiotherapy after radical prostatectomy; treatment outcomes and failure patterns
35. 111In-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer following radical prostatectomy
36. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
37. 111capromab pendetide
38. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy
39. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint® scanning in prostatic cancer patients
40. Preliminary imaging results utilizing indium-111 labeled CYT-356 (ProstaScint™) in the detection of recurrent prostate cancer
41. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
42. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
43. An expressed-sequence-tag database of the human prostate; sequence analysis of 1168 cDNA clones